

**Table S1.** Differences in demographic and clinical characteristics between participants in the study sample and participants excluded due to missing baseline data.

| Variable   | Excluded<br><i>n</i> =1608 (62.08%) | Included<br><i>n</i> =982 (37.92%) | p-value |
|--|-------------------------------------|------------------------------------|---------|
| ART regimen category                                   |                                     |                                    | 0.406   |
| Boosted PI <sup>1</sup>                                | 618 (38.43%)                        | 352 (35.85%)                       |         |
| NNRTI <sup>2</sup>                                     | 578 (35.95%)                        | 364 (37.07%)                       |         |
| INSTI <sup>3</sup>                                     | 412 (25.62%)                        | 266 (27.09%)                       |         |
| Age at ART initiation (years)                          | 35.9 (30.3, 44.0)                   | 35.2 (29.7, 42.9)                  | 0.010   |
| Female sex   | 202 (12.56%)                        | 80 (8.15%)                         | <0.001  |
| Transmission mode                                      |                                     |                                    | <0.001  |
| MSM <sup>4</sup>                                       | 1026 (63.81%)                       | 665 (67.72%)                       |         |
| PWID <sup>5</sup>                                      | 170 (10.57%)                        | 129 (13.14%)                       |         |
| Heterosexual   | 292 (18.16%)                        | 144 (14.66%)                       |         |
| NA <sup>6</sup>  | 120 (7.46%)                         | 44 (4.48%)                         |         |
| Ethnic/racial group                                    | 10.00 (10.00, 10.00)                | 10.00 (10.00, 10.00)               | <0.001  |
| White  | 1492 (92.79%)                       | 918 (93.48%)                       |         |
| Black  | 79 (4.91%)                          | 9 (0.92%)                          |         |
| Asian  | 10 (0.62%)                          | 3 (0.31%)                          |         |
| Middle East/Arab                                       | 3 (0.19%)                           | 0 (0.00%)                          |         |
| NA <sup>6</sup>  | 24 (1.49%)                          | 52 (5.30%)                         |         |
| Year of ART initiation                                 | 2013 (2011, 2015)                   | 2013 (2011, 2015)                  | 0.176   |
| AIDS before baseline                                   | 141 (8.77%)                         | 42 (4.28%)                         | <0.001  |
| Baseline <sup>7</sup> CD4 (cells/μl)                   | 306 (180, 417)                      | 325 (212, 428)                     | 0.002   |
| Baseline <sup>7</sup> HIV-RNA (log <sub>10</sub> c/ml) | 4.50 (3.86, 5.10)                   | 4.50 (3.94, 4.99)                  | 0.769   |

<sup>1</sup>Protease Inhibitors; <sup>2</sup>Non-Nucleoside Reverse Transcriptase Inhibitors; <sup>3</sup>Integrase Strand Inhibitors; <sup>4</sup>Men having sex with men; <sup>5</sup>People who inject drugs; <sup>6</sup>Non-Available; <sup>7</sup>At ART initiation, available for 1498/1608 (CD4) and 1525/1608 (HIV-RNA).




Figure S1. Flowchart for inclusion/exclusion criteria.